AlphAIAlphAI — Financial news for AI agents
yahoo.comSEP 171 min read$STE

STERIS Stock: Is STE Underperforming the Healthcare Sector?

STERIS (STE) has outperformed Abbott Laboratories (ABT) year-to-date and over the past 52 weeks. Analysts give STE a 'Moderate Buy' rating with a mean price target of $263.75, implying 25.4% upside.

Original reporting
yahoo.com
Published Sep 17, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
STERIS Stock: Is STE Underperforming the Healthcare Sector? — source image
Source · yahoo.com
Decision brief

The 30-second read

$STEBullishLow
01

Why it matters

Analyst consensus may influence short-term trading but lacks a strong catalyst.

02

Market read

Provides a modest upgrade signal for STE investors.

03

What to watch

Potential supply-chain constraints and competitive pressure from peers like Abbott.

Relevance 5/10Novelty 5/10Timing: current

Background

Steris (STE) is compared to Abbott Laboratories, which has underperformed.

Company-level read

Ticker impact

$STEBullishMedium confidence
Context

Analysts maintain a Moderate Buy rating with a $263.75 price target, implying 25.4% upside.

Expected impact

Potential modest upside if market prices adjust toward the target.

Evidence & confidence

The rating and target are fresh information but lack a catalyst that would drive a rapid move.

Market effects

Sector

May slightly improve sentiment toward the broader healthcare equipment sector.

Regional

Limited to U.S. markets where Steris trades.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The price target could be overly optimistic given recent sector weakness.

Key entities

  • Company
    Steris plc

    US‑listed medical device manufacturer (ticker STE).

Read at source← All news

Related articles

AUG 26
$STEHighAI 8/10

STERIS Stock Outlook: Is Wall Street Bullish or Bearish?

STERIS plc (STE), a provider of infection prevention products, reported mixed Q2 2026 earnings with revenue of $1.5B, up 7.3% YoY, and adjusted EPS of $2.59, beating estimates. Free cash flow margin declined to 18.7% from 23.5% YoY. Analysts expect EPS to rise 9.1% for the year ending March 2027. The stock has underperformed the S&P 500 and XLV ETF over the past year and 2026. Analysts' consensus is 'Moderate Buy' with a mean price target of $263.75, implying 11.6% upside.

barchart.com2 min
AUG 9
$STEMed

STERIS Q1 Earnings Call Highlights

STERIS (NYSE:STE) reported Q1 Healthcare capital equipment revenue up 1% and ending backlog at $444 million, while capital equipment orders rose 4%. Healthcare EBIT margin increased 60 bps to 24.8%. Life Sciences organic revenue grew 8% and EBIT margin fell to 42.1%. STERIS plans a $600 million North Carolina chemistry center, with FY2027 EPS guidance $11.10 to $11.30.

finance.yahoo.com4 min
AUG 5
$STEMed

STERIS plc (STE): Results of Operations and Financial Condition

STERIS plc (STE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2027 First Quarter • Fiscal 2027 first quarter revenue increased 7%; constant currency organic revenue growth was 6% • Fiscal 2027 first quarter as reported diluted EPS increased to $2.04; adjusted EPS per diluted share i

SEC EDGAR 8-K6 min
MAY 27
$STEMedAI 8/10

Are Wall Street Analysts Predicting STERIS Stock Will Climb or Sink?

STERIS plc (STE) has lagged the market, falling 11.2% over the past year versus a 27.9% S&P 500 gain, and is down 14.6% in 2026 YTD. After Q4 results on May 11 (revenue $1.6B, +7.3% YoY; adjusted EPS $2.83, +3.3%), analysts expect FY2027 EPS of $11.18 (+9.9%). Consensus is “Moderate Buy” (5 “Strong Buy,” 3 “Hold”); KeyBanc cut its target to $269.

finance.yahoo.com4 min
SEP 17
$GOOGLMed

Tigress Financial raises Alphabet stock price target on AI growth

Tigress Financial raised Alphabet's (GOOGL) price target to $485 from $415, citing AI-driven growth in Search, Cloud, and YouTube. The firm highlighted strong Q2 results, 20% revenue growth to $445.87B, and a P/E ratio of 17.38. Alphabet's AI investments are expected to boost long-term economic profit growth. Recent product updates include Gemini AI enhancements and new apps.

investing.com2 min